^
Association details:
| Biomarker: | ZEB2-JAK2 fusion |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | CHZ868 (JAK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
150 Novel Drugs to Target JAK2 Rearrangements in Pediatric Acute Lymphoblastic Leukemia
Published date:
11/03/2022
Excerpt:
Finally, we demonstrated the in vivo efficacy of CHZ868 in PAX5::JAK2, ATF7IP::JAK2 and ZEB2::JAK2 patient-derived- xenografts.
DOI:
https://doi.org/10.1182/blood-2022-169437
